Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bug may predict prostate cancer drug response

NCT ID NCT06242509

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated May 14, 2026

Summary

This study looks at whether a specific gut bacteria, Akkermansia muciniphila, can help predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will measure the bacteria levels in stool samples before and after treatment. The goal is to see if changes in this bacteria can serve as a simple, non-invasive marker of treatment success. About 52 men with metastatic castration-resistant prostate cancer will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpital Saint Louis AP-HP

    RECRUITING

    Paris, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER